Ferring would like to use cookies to better understand your use of this website and improve your experience while navigating it. Please accept our use of cookies in accordance with our privacy policy. 

Accept / Decline

Business Development

What are we looking for?

Ferring's primary business development objective is to complement the company's portfolio. A key strategic objective is to grow our business in the United States and Japan. In particular, the company is interested in late-stage products (phase IIb and onwards), as well as products already marketed globally and regionally.

Areas of interest


    • Over the next few years Ferring will be looking for products to supplement PENTASA® and its R&D gastro pipeline for the treatment of Crohn's disease and ulcerative colitis.
    • Long term, Ferring is interested in new treatment options for inflammatory bowel diseases and other lower gastro-intestinal conditions.
    • Long term, Ferring is looking to develop the next generation of the GLYPRESSIN®-inspired treatments.

Reproductive health

Ferring Pharmaceuticals is committed to obstetrics and gynaecology where its existing products concentrate on utilising the body's natural processes to help couples conceive and to ensure a successful pregnancy.

By being able to offer new and innovative products in these areas, it is Ferring's vision to provide the best treatments to aid every stage of the reproductive cycle. 

Furthermore Ferring aims to help women to overcome and live with diseases of the Reproductive System.


Ferring is interested in innovative products to supplement its existing portfolio of drugs in the Urology and Uro-Oncology area.

We are also receptive to considering opportunities targeting specialty physician segments which may be outside of our core therapeutic areas.


Ferring Canada
200 Yorkland Boulevard, Suite 500
Toronto, Ontario, M2J 5C1 

Tel:  +1 416 490 0121 or +1 800 263 4057
Fax: 416 493 1692